Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy

Bibliography

• CDC. National surveillance of cocaine use and related health consequences. MMWR Weekly 1982.31:265-8, 273 Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001101.htm
   Google Scholar
• Available from: http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf United Nations, NY 2012
   Google Scholar
• Degenhardt L, Baxter AJ, Lee YY, et al. Global epidemiology and burden of disease of psychostimulant dependence: findings from global burden of disease study 2010. Drug Alcohol Depend 2014;137:36-47
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795 Substance Abuse and Mental Health Services Administration; Rockville, MD: 2013
   Google Scholar
• Ettner SL, Huang D, Evans E, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment “pay for itself”? Health Serv Res 2006;41:192-213
   PubMed Web of Science ®Google Scholar
• Hiller ML, Knight K, Simpson DD. Recidivism following mandated residential substance abuse treatment for felony probationers. Prison J 2006;86:230-41
   Web of Science ®Google Scholar
• McCollister KE, French MT, Inciardi JA, et al. Post-release substance abuse treatment for criminal offenders: a cost-effectiveness analysis. J Quant Criminol 2003;19:389-407
   Web of Science ®Google Scholar
• Laudet AB. Rates and predictors of employment among formerly polysubstance dependent urban individuals in recovery. J Addict Dis 2012;31:288-302
   PubMed Web of Science ®Google Scholar
• Naderi-Heiden A, Gleiss A, Backer C, et al. Mortality and employment after in-patient opiate detoxification. Eur Psychiatry 2012;27:294-300
   PubMed Web of Science ®Google Scholar
• Flynn PM, Kristiansen PL, Porto JV, Hubbard RL. Costs and benefits of treatment for cocaine addiction in DATOS. Drug Alcohol Depend 1999;57:167-74
   PubMed Web of Science ®Google Scholar
• Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 2003;25:125-34
   PubMed Web of Science ®Google Scholar
• Olmstead TA, Petry NM. The cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend 2009;102:108-15
   PubMed Web of Science ®Google Scholar
• Prah Ruger J, Abdallah AB, Luekens C, Cottler L. Cost-effectiveness of peer-delivered interventions for cocaine and alcohol abuse among women: a randomized controlled trial. PLoS One 2012;7(3):e33594
   PubMedGoogle Scholar
• Cartwright WS. Cocaine medications, cocaine consumption, and societal costs. Pharmacoeconomics 2000;18:405-13
   PubMed Web of Science ®Google Scholar
• Jofre-Bonet M, Sindelar JL, Petrakis IL, et al. Cost effectiveness of disulfiram: treating cocaine use in methadone-maintained patients. J Subst Abuse Treat 2004;26:225-32
   PubMed Web of Science ®Google Scholar
• Shearer J, Shanahan M, Darke S, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev 2010;29:235-42
   PubMed Web of Science ®Google Scholar
• Johanson CD, Fischman MW. The pharmacology of cocaine related to its abuse. Pharmacol Rev 1989;41:3-52
   PubMed Web of Science ®Google Scholar
• Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 2003;479:23-40
   PubMed Web of Science ®Google Scholar
• Parsons LH, Justice JB. Serotonin and dopamine sensitization in the nucleus accumbens, ventral tegmental area and dorsal raphe nucleus following repeated cocaine administration. J Neurochem 1993;61:1611-19
   PubMed Web of Science ®Google Scholar
• Pentkowski NS, Acosta JI, Browning JR, et al. Stimulation of 5-HT(1B) receptors enhances cocaine reinforcement yet reduces cocaine-seeking behavior. Addict Biol 2009;14:419-30
   PubMed Web of Science ®Google Scholar
• French MT, McGeary KA, Chitwood DD, et al. Chronic illicit drug use, health services utilization and the cost of medical care. Soc Sci Med 2000;50:1703-13
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Bacchetti P, Osmond D, et al. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA 1989;261:561-5
   PubMed Web of Science ®Google Scholar
• Chaisson MA, Stoneburner RL, Hildebrandt DS, et al. Heterosexual transmission of HIV-1 associated with the use of smokeable freebase cocaine (crack). AIDS 1991;5:1121-6
   PubMed Web of Science ®Google Scholar
• Estrada AL. Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users. Public Health Rep 2002;117:S126-34
   PubMed Web of Science ®Google Scholar
• Carvalho HB, Seibel SD. Crack cocaine use and its relationship with violence and HIV.Clinics (Sao Paulo). 2009;64:857-66
   Google Scholar
• Falck RS, Wang J, Carlson RG, et al. The prevalence and correlates of depressive symptomatology among a community sample of crack-cocaine smokers. J Psychoactive Drugs 2002;34:281-8
   PubMed Web of Science ®Google Scholar
• Najavits LM, Runkel R, Neuner C, et al. Rates and symptoms of PTSD among cocaine-dependent patients. J Stud Alcohol 2003;64:601-6
   PubMed Web of Science ®Google Scholar
• Gudjonsson GH, Sigurdsson JF, Sigfusdottir ID, et al. An epidemiological study among young persons and the relationship with cigarette smoking, alcohol consumption, and illicit drug use. J Child Psychol Psychiatry 2012;53:304-12
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No.(SMA) 13-4760, DAWN Series D-39 Substance Abuse and Mental Health Services Administration; Rockville, MD: 2013
   Google Scholar
• Volkow ND, Wang GJ, Fischman MW, et al. Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci 2000;67:1507-15
   PubMed Web of Science ®Google Scholar
• Resnick RB, Kestenbaum RS, Schwartz LK. Acute systemic effects of cocaine in man: a controlled study by intranasal and intravenous routes. Science 1977;195:696-8
   PubMed Web of Science ®Google Scholar
• Perez-Reyes M, Di Guiseppi S, Ondrusek G, et al. Free-base cocaine smoking. Clin Pharmacol Ther 1982;32:459-65
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-18
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Brown S, Dudish-Poulsen S, et al. Individual differences in the subjective response to smoked cocaine in humans. Am J Drug Alcohol Abuse 2000;26:591-602
   PubMed Web of Science ®Google Scholar
• Kosten TR. Pathophysiology and treatment of cocaine dependence. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Lippincott Williams & Wilkins; Baltimore, MD: 2002. p. 1461-73
   Google Scholar
• Menaker J, Farcy DA, Boswell SH, et al. Cocaine-induced agitated delirium with associated hyperthermia: a case report. J Emerg Med 2011;41:e49-53
   PubMedGoogle Scholar
• Wetli CV, Mash D, Karch SB. Cocaine-associated agitated delirium and the neuroleptic malignant syndrome. Am J Emerg Med 1996;14:425-8
   PubMed Web of Science ®Google Scholar
• Brady KT, Lydiard RB, Malcolm R, et al. Cocaine-induced psychosis. J Clin Psychiatry 1991;52:509-12
   PubMed Web of Science ®Google Scholar
• Hayes BD, Martinez JP, Barrueto FJr. Drug-induced hyperthermic syndromes: part I. Hyperthermia in overdose. Emerg Med Clin North Am 2013;31:1019-33
   PubMed Web of Science ®Google Scholar
• Hoffman RS. Treatment of patients with cocaine-induced arrhythmias: bringing the bench to the bedside. Br J Clin Pharmacol 2010;69:448-57
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association, Washington, DC: 2013
   Google Scholar
• Gawin FH, Ellinwood EH. Cocaine and other stimulants: actions, abuse, and treatment. N Engl J Med 1988;318:1173-82
   PubMed Web of Science ®Google Scholar
• Walsh SL, Stoops WW, Moody DE, et al. Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal and pharmacokinetics. Exp Clin Psychopharmacol 2009;17:205-16
   PubMed Web of Science ®Google Scholar
• Ahmadi J, Kampman K, Dackis C, et al. Cocaine withdrawal symptoms identify “Type B” cocaine-dependent patients. Am J Addict 2008;17:60-4
   PubMed Web of Science ®Google Scholar
• Kampman K, Alterman AI, Volpicelli JR, et al. Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment. Psychol Addict Behav 2001;15:52-9
   PubMed Web of Science ®Google Scholar
• Kampman K, Pettinati H, Volpicelli JR, et al. Cocaine dependence severity predicts outcome in outpatient detoxification from cocaine and alcohol. Am J Addict 2004;13:74-82
   PubMed Web of Science ®Google Scholar
• Koob GF. Dynamics of neuronal circuits in addiction: reward, antireward, and emotional memory. Pharmacopsychiatry 2009;42:S32-41
   PubMed Web of Science ®Google Scholar
• Skolnick P, Volkow ND. Addiction therapeutics: obstacles and opportunities. Biol Psychiatry 2012;72:890-1
   PubMed Web of Science ®Google Scholar
• Mroziewicz M, Tyndale RF. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 2010;5:17-29
   PubMedGoogle Scholar
• Ciraulo DA, Piechniczek-Buczek J, Iscan EN. Outcome predictors in substance use disorders. Psychiatr Clin North Am 2003;26:381-409
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Pavlicova M, Bisaga A, et al. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry 2012;72:950-6
   PubMed Web of Science ®Google Scholar
• Carboni E, Spielewoy C, Vacca D, et al. Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene. J Neurosci 2001;21:141-4
   Google Scholar
• Mead AN, Rocha BA, Donovan DM, et al. Intravenous cocaine induced-activity and behavioural sensitization in norepinephrine-, but not dopamine-transporter knockout mice. Eur J Neurosci 2002;16:514-20
   PubMed Web of Science ®Google Scholar
• Drouin C, Darracq L, Trovero F, et al. Alpha-1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 2002;22:2873-84
   PubMed Web of Science ®Google Scholar
• Belzung C, Scearce-Levie K, Barreau S, et al. Absence of cocaine-induced place conditioning in serotonin 1B receptor knock-out mic. Pharmacol Biochem Behav 2000;66:221-5
   PubMed Web of Science ®Google Scholar
• Paladini CA, Williams JT. Noradrenergic inhibition of midbrain dopamine neurons. J Neurosci 2004;24:4568-75
   PubMed Web of Science ®Google Scholar
• Blanc G, Trovero F, Vezina P, et al. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical d-amphetamine injection. Eur J Neurosci 1994;6:293-8
   PubMed Web of Science ®Google Scholar
• Pozzi L, Invernizzi R, Cervo L, et al. Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 1994;63:195-200
   PubMed Web of Science ®Google Scholar
• Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 2003;42:33-84
   PubMed Web of Science ®Google Scholar
• Parsons LH, Koob GF, Weiss F. Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration. Behav Brain Res 1996;73:225-8
   PubMed Web of Science ®Google Scholar
• Parsons LH, Koob GF, Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995;274:1182-91
   PubMed Web of Science ®Google Scholar
• Cunningham KA, Anastasio NC. Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. Neuropharmacology 2014;76:460-78
   PubMed Web of Science ®Google Scholar
• McFarland K, Lapish CC, Kalivas PW. Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J Neurosci 2003;23:3531-7
   PubMed Web of Science ®Google Scholar
• Schmidt HD, Schassburger RL, Guercio LA, et al. Stimulation of mGluR5 in the accumbens shell promotes cocaine seeking by activating PKC gamma. J Neurosci 2013;33:14160-9
   PubMed Web of Science ®Google Scholar
• Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict 2007;16:71-8
   PubMed Web of Science ®Google Scholar
• Simpson DD, Joe GW, Fletcher BW, et al. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999;56:507-14
   PubMed Web of Science ®Google Scholar
• Hornykiewicz O. The mechanisms of action of L-DOPA in Parkinson’s disease. Life Sci 1974;15:1249-59
   PubMed Web of Science ®Google Scholar
• Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:537-43
   PubMed Web of Science ®Google Scholar
• Amato L, Minozzi S, Pani PP, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database Syst Rev 2011;12:CD003352
   PubMedGoogle Scholar
• Mooney ME, Schmitz JM, Moeller FG, et al. Safety, tolerability and efficacy of levodopa-carbidopa for cocaine dependence: two double-blind, randomized, clinical trials. Drug Alcohol Depend 2007;88:214-23
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Lindsay JA, Stotts AL, et al. Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of behavioral targets. Exp Clin Psychopharmacol 2010;18:238-44
   PubMed Web of Science ®Google Scholar
• Liu S, Green CE, Lane SD, et al. The influence of dopamine-B-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genomics 2014;24:370-3
   PubMed Web of Science ®Google Scholar
• Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 2002;11:491-9
   PubMed Web of Science ®Google Scholar
• Volkow ND, Ding YS, Fowler JS, et al. Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 1996;15:55-71
   PubMed Web of Science ®Google Scholar
• Fleckenstein AE, Volz TJ, Riddle EL, et al. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007;47:681-98
   Google Scholar
• Rush CR, Stoops WW, Hays LR. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability, and efficacy. Drug Alcohol Depend 2009;99:261-71
   PubMed Web of Science ®Google Scholar
• Rush CR, Stoops WW, Sevak RJ, et al. Cocaine choice in humans during D-amphetamine maintenance. J Clin Psychopharmacol 2010;30:152-9
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Lundahl L, Steinmiller CL. Sustained release d-amphetamine reduces cocaine but not ‘speedball’-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusers. Neuropsychopharmacology 2010;35:2624-37
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21:522-6
   PubMed Web of Science ®Google Scholar
• Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-81
   PubMed Web of Science ®Google Scholar
• Shearer J, Wodak A, van Beek I, et al. Pilot randomized double blind placebo-controlled study of dextroamphetamine for cocaine dependence. Addiction 2003;98:1137-41
   PubMed Web of Science ®Google Scholar
• Darracq L, Blanc G, Glowinski J, et al. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of d-amphetamine. J Neurosci 1998;18:2729-39
   PubMed Web of Science ®Google Scholar
• Zhang XY, Kosten TA. Prazosin, an alpha-1 adrenergic antagonist, reduces cocaine-induced reinstatement of drug-seeking. Biol Psychiatry 2005;57:1202-4
   PubMed Web of Science ®Google Scholar
• Zhang XY, Kosten TA. Previous exposure to cocaine enhances cocaine self-administration in an alpha-1 adrenergic receptor manner. Neuropsychopharmacology 2007;32:638-45
   PubMed Web of Science ®Google Scholar
• Shorter D, Lindsay JA, Kosten TR. The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study. Drug Alcohol Depend 2013;131:66-70
   PubMed Web of Science ®Google Scholar
• Gaval-Cruz M, Weinshenker D. Mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse. Mol Interv 2009;9:175-87
   PubMed Web of Science ®Google Scholar
• Kitson TM. The disulfiram-ethanol reaction: a review. J Stud Alcohol 1977;38:96-113
   PubMed Web of Science ®Google Scholar
• Bourdelat-Parks BN, Anderson GM, Donaldson ZR, et al. Effects of dopamine-beta-hydroxylase genotype and disulfiraminhibition on catecholamine homeostasis in mice. Psychopharmacology (Berl) 2005;183:72-80
   PubMed Web of Science ®Google Scholar
• Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998;93:713-27
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Kosten TR, Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 1998;52:27-39
   PubMed Web of Science ®Google Scholar
• Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 2000;95:219-28
   PubMed Web of Science ®Google Scholar
• Oliveto A, Poling J, Mancino MJ, et al. Randomized, double-blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug Alcohol Depend 2011;113:184-91
   PubMed Web of Science ®Google Scholar
• Schottenfeld RS, Chawarski MC, Cubells JF, et al. Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. Drug Alcohol Depend 2014;136:36-42
   PubMed Web of Science ®Google Scholar
• Carroll KM, Nich C, Shi JM, et al. Efficacy of disulfiram and twelve step facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trial. Drug Alcohol Depend 2012;126:224-31
   PubMed Web of Science ®Google Scholar
• Kosten TR, Wu G, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine beta-hydroxylase. Biol Psychiatry 2013;73:219-24
   PubMed Web of Science ®Google Scholar
• Spellicy CJ, Kosten TR, Hamon SC, et al. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.PharmacogenetGenom. 2013;23:333-40
   Google Scholar
• Shorter D, Nielsen DA, Huang W, et al. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and alpha1a-adrenoceptor gene variation. Eur Neuropsychopharmacol 2013;23:1401-7
   PubMed Web of Science ®Google Scholar
• Weinshenker D. Cocaine sobers up. Nat Med 2010;16:969-70
   PubMed Web of Science ®Google Scholar
• Schroeder JP, Epps SA, Grice TW, et al. The selective dopamine beta-hydroxylase inhibitor nepicastat attenuates multiple aspects of cocaine-seeking behavior. Neuropsychopharmacology 2013;38:1032-8
   PubMed Web of Science ®Google Scholar
• Cooper DA, Kimmel HL, Manvich DF, et al. Effects of pharmacologic dopamine beta-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys. J Pharmacol ExpTher 2014;350:144-52
   PubMed Web of Science ®Google Scholar
• Cunningham KA, Carbone CL, Anastasio NC, et al. Dopamine beta-hydroxylase inhibitor SYN117 decreases subjective effects of cocaine. College on Problems of Drug Dependence Annual Meeting Abstract #135; 2010. Available from: http://www.cpdd.vcu.edu/Pages/Meetings/Meetings_PDFs/2010Programbook.pdf
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01704196?term=nepicastat&rank=2
   Google Scholar
• Reis AD, Castro LA, Faria R, et al. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008;30:132-5
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75:233-40
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Wang XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013;70:1338-46
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013;133:94-9
   PubMed Web of Science ®Google Scholar
• Umbricht A, DeFulio A, Winstanley EL, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend 2014;140:92-100
   PubMed Web of Science ®Google Scholar
• Kalivas PW. Neurobiology of cocaine addiction: implications for new pharmacotherapy. Am J Addict 2007;16:71-8
   PubMed Web of Science ®Google Scholar
• Peng XQ, Li X, Gilbert JG, et al. Gamma-vinyl GABA inhibits cocaine-triggered reinstatement of drug-seeking behavior in rats by a non-dopaminergic mechanism. Drug Alcohol Depend 2008;97:216-25
   PubMed Web of Science ®Google Scholar
• Schiffer WK, Marsteller D, Dewey SL. Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacology (Berl) 2003;168:339-43
   PubMed Web of Science ®Google Scholar
• Brodie JD, Figueroa E, Dewey SL. Treating cocaine addiction: from preclinical to clinical trial experience with gamma-vinyl GABA. Synapse 2003;50:261-5
   PubMed Web of Science ®Google Scholar
• Brodie JD, Case BG, Figueroa E, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. Am J Psychiatry 2009;166:1269-77
   PubMed Web of Science ®Google Scholar
• Somoza EC, Winship D, Gorodetzky CW, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013;70:630-7
   Google Scholar
• Berezina TL, Khouri AS, Winship MD, et al. Visual field and ocular safety during short-term vigabatrin treatment in cocaine abusers. Am J Ophthalmol 2012;154:326-32
   PubMed Web of Science ®Google Scholar
• Pan Y, Gerasimov MR, Kvist T, et al. CPP-115, a potent gamma-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction. J Med Chem 2012;55:357-66
   PubMed Web of Science ®Google Scholar
• Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67:554-66
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, O’Connor WT, et al. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1988;253:135-8
   Google Scholar
• Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999;20:346-56
   PubMed Web of Science ®Google Scholar
• Kalivas PW. The glutamate homeostasis hypothesis of addiction. Nat Rev Neurosci 2009;10:561-72
   PubMed Web of Science ®Google Scholar
• Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70:29-37
   PubMed Web of Science ®Google Scholar
• Anderson AL, Reid MS, Li SH, et al. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 2009;104:133-9
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-11
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012;43:303-12
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Rathnayaka N, Green CE, et al. Combination of modafinil and d-amphetamine for the treatment of cocaine dependence: a preliminary investigation. Front Psychiatry 2012;3:77
   PubMedGoogle Scholar
• Schmitz JM, Green CE, Stotts AL, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone. Drug Alcohol Depend 2014;136:100-7
   PubMed Web of Science ®Google Scholar
• Tonstad S, Heggen E, Giljam H, et al. Niccine®, a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 2013;15:1492-501
   PubMed Web of Science ®Google Scholar
• Hoogsteder PH, Kotz D, van Spiegel PI, et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX®) or placebo co-administered with varenicline (Champix®) for smoking cessation: study protocol of a phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health 2012;12:1052
   PubMed Web of Science ®Google Scholar
• Fahim RE, Kessler PD, Kalnik MW. Therapeutic vaccines against tobacco addiction. Expert Rev Vaccines 2013;12:333-42
   PubMed Web of Science ®Google Scholar
• Shen XY, Kosten TA, Lopez AY, et al. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend 2013;129:41-8
   PubMed Web of Science ®Google Scholar
• Kosten TA, Shen XY, O’Malley PW, et al. A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats. Prog Neuropsychopharmacol Biol Psychiatry 2013;45:223-9
   PubMed Web of Science ®Google Scholar
• Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996;2:1129-32
   PubMed Web of Science ®Google Scholar
• Orson FM, Kinsey BM, Singh RA, et al. Vaccines for cocaine abuse. Hum Vaccin 2009;5:194-9
   PubMed Web of Science ®Google Scholar
• Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002;20:1196-204
   PubMed Web of Science ®Google Scholar
• Martell BA, Mitchell E, Poling J, et al. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58:158-64
   PubMed Web of Science ®Google Scholar
• Martell BA, Orson FM, Poling J, et al. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double=blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009;66:1116-23
   PubMed Web of Science ®Google Scholar
• Kosten TR, Domingo CB, Shorter D, et al. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend 2014;140:42-7
   PubMed Web of Science ®Google Scholar
• Stoops WW, Glaser PE, Fillmore MT, et al. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 2004;18:534-43
   PubMed Web of Science ®Google Scholar
• Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60
   PubMed Web of Science ®Google Scholar
• Vosburg SK, Hart CL, Haney M, et al. Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 2010;106:233-6
   PubMed Web of Science ®Google Scholar